OSAM
LCTX icon

O'Shaughnessy Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-396
Closed -$1K – 1909
2021
Q3 		$1K Sell
396
-144
-27% -$369 ﹤0.01% 2595
2021
Q2 		$2K Hold
540
– – ﹤0.01% 2312
2021
Q1 		$1K Buy
540
+539
+53,900% +$1.29K ﹤0.01% 2212
2020
Q4 		$0 Hold
1
– – ﹤0.01% 2155
2020
Q3 		$0 Hold
1
– – ﹤0.01% 1935
2020
Q2 		$0 Hold
1
– – ﹤0.01% 1809
2020
Q1 		$0 Hold
1
– – ﹤0.01% 1569
2019
Q4 		$0 Buy
+1
New +$1 ﹤0.01% 1858

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

O'Shaughnessy Asset Management's LCTX Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2021, closing a stake of 396 shares — an estimated $1K sold.

O'Shaughnessy Asset Management first reported a position in LCTX in Q4 2019 and held it in 8 quarters. The position peaked at $2K in Q2 2021. 124 funds tracked by Wall St. Rank hold LCTX as of Q4 2021.

  • O'Shaughnessy Asset Management reported no remaining Lineage Cell Therapeutics position as of Q4 2021 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 396 Lineage Cell Therapeutics shares in Q4 2021, an estimated $1K.
  • O'Shaughnessy Asset Management first reported a position in Lineage Cell Therapeutics in Q4 2019 and held it in 8 quarters.
  • O'Shaughnessy Asset Management's Lineage Cell Therapeutics position peaked at $2K in Q2 2021.
  • 124 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.